γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria

Noguera-Ortega, Estela; Rabanal, Rosa M.; Secanella-Fandos, Silvia; Torrents, Eduard; Luquin, Marina; Julián, Esther

doi:10.1016/j.juro.2015.07.011

Cited by 14 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We recently demonstrated the antitumor and immunomodulatory activity of this mycobacterium ( 4 , 5 ). In vitro studies have shown the capacity of M. brumae to activate macrophages.…”

Section: Genome Announcementmentioning

confidence: 99%

Draft Genome Sequence of Mycobacterium brumae ATCC 51384

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…We recently demonstrated the antitumor and immunomodulatory activity of this mycobacterium ( 4 , 5 ). In vitro studies have shown the capacity of M. brumae to activate macrophages.…”

Section: Genome Announcementmentioning

confidence: 99%

Draft Genome Sequence of Mycobacterium brumae ATCC 51384

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Between both treatments, γ-irradiated mycobacteria trigger cytokine levels closer to those induced by live mycobacteria, than those induced by HK mycobacteria. Regarding immune activation: induction of cytotoxicity by activated cells, induction of cytokine production, and expression of activation markers on immune cells, again the immune response induced by live mycobacteria was higher than that triggered by non-viable mycobacteria [63,66,70,71].…”

Section: Purified Mycobacteria Antigens and Non-viable Mycobacteriamentioning

confidence: 95%

“…Interestingly, when live BCG or M. brumae was instilled in the first week of treatment and subsequent instillations were done using γ-irradiated mycobacteria, significant prolonged survival rates were observed in tumor-bearing mice compared to untreated mice [71].…”

Section: Purified Mycobacteria Antigens and Non-viable Mycobacteriamentioning

confidence: 99%

Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers

Noguera-Ortega¹,

Julián²

2018

Mycobacterium - Research and Development

Self Cite

View full text Add to dashboard Cite

Mycobacteria are the unique group of bacteria that are currently used in antitumoral immunotherapy. Specifically, intravesical instillation of viable cells of Mycobacterium bovis Bacillus Calmette-Guérin (BCG), after transurethral resection of non-muscle invasive bladder cancer, is the most efficacious treatment for avoiding recurrence and progression of the disease. BCG has been used for the last 35 years for bladder cancer treatment, but other mycobacteria or mycobacteria components are currently under preclinical and clinical studies for the immunotherapeutic treatment of non-invasive bladder cancer and also of other types of tumors located at the urinary system. Those are, for instance, cell wall extracts or heat-killed forms from BCG or other mycobacteria such as Mycobacterium phlei or Mycobacterium indicus pranii (MIP) or even viable cells from non-pathogenic mycobacteria such us Mycobacterium brumae. A review of the literature in which mycobacteria components, non-viable mycobacteria, and viable mycobacteria have been used for these different cancers will be performed. In this chapter, the function of mycobacteria as antitumor agents will be then analyzed, awarding the audience a broad knowledge of one of the beneficial applications of mycobacteria, which are usually introduced as dangerous microorganisms.

show abstract

“…The idea to inactivate BCG by heat, irradiation, or formaldehyde in order to prevent its side effects due to the living bacteria is already old, but recently was addressed again in preclinical studies. 38 , 39 However, one is far from clinical application. Anyhow, one may expect that, if inactivated BCG keeps its therapeutic effect, the side effects due to the immune response will remain.…”

Section: Prevention Strategies To Diminish Toxicitymentioning

confidence: 99%

Managing the adverse events of intravesical bacillus Calmette–Guérin therapy

Decaestecker¹,

Oosterlinck²

2015

RRU

View full text Add to dashboard Cite

This paper provides recommendations on the management of complications arising from intravesical treatment with bacillus Calmette–Guérin (BCG) for nonmuscle-invasive bladder tumors. There is minimal recommendations currently available as randomized trials on the side effects of intravesical BCG are lacking and severe complications are usually described in case reports only. All physicians giving intravesical BCG should be aware of the possible complications that could arise and how to treat these. The incidence of bladder irritation, general malaise, and fever is very high, while severe complications remain rare. Approximately 8% of patients have to stop treatment because of these complications. BCG infections and reactions can occur anywhere in the body, and may happen straight away or even several months or years after BCG treatment, making early diagnosis difficult. Additionally, correct diagnosis is hampered by the uncertain appearance of BCG in tissue and body fluid. An essential step in the management complications arising from BCG is written information for both the family doctor and the patient on the possible adverse events and their management. Recent data demonstrated that none of the earlier advocated methods to prevent BCG toxicity are valid: lowering the dose, tuberculostatic drugs, or oxybutynin. Severe complications are treated with three or four tuberculostatics over 3–12 months, depending on the severity of the situation. Corticosteroids are an essential therapy in BCG septicemia. Nonsteroidal anti-inflammatory drugs and corticosteroids can manage efficiently the immunological complications.

show abstract

γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria

Abstract: Our results show that although γ irradiated mycobacteria is less efficacious than live mycobacteria, it induces an antitumor effect in vivo, avoiding the possibility of further mycobacterial infections.

Cited by 14 publications

References 26 publications

Draft Genome Sequence of Mycobacterium brumae ATCC 51384

Draft Genome Sequence of Mycobacterium brumae ATCC 51384

Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers

Managing the adverse events of intravesical bacillus Calmette–Guérin therapy

Contact Info

Product

Resources

About

γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria

Abstract: Our results show that although γ irradiated mycobacteria is less efficacious than live mycobacteria, it induces an antitumor effect in vivo, avoiding the possibility of further mycobacterial infections.

Cited by 14 publications

References 26 publications

Draft Genome Sequence of Mycobacterium brumae ATCC 51384

Draft Genome Sequence of Mycobacterium brumae ATCC 51384

Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers

Managing the adverse events of intravesical bacillus Calmette&ndash;Gu&eacute;rin therapy

Contact Info

Product

Resources

About

Managing the adverse events of intravesical bacillus Calmette–Guérin therapy